

Paper No. ____
Filed: April 12, 2022

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS, INC., CELLTRION, INC., and
APOTEX, INC.,
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

IPR2021-00880¹
Patent No. 9,669,069

PETITIONER UPDATED EXHIBIT LIST

¹ IPR2022-00257 has been joined with this proceeding.

| Exhibit No. | Description |
|-------------|---|
| 1001 | U.S. Patent No. 9,669,069 B2 (“’069 patent”) |
| 1002 | Expert Declaration of Dr. Thomas A. Albin in Support of Petition for <i>Inter Partes</i> Review of Patent No. 9,669,069 B2, dated May 4, 2021 (“Albin”) |
| 1003 | Expert Declaration of Mary Gerritsen, Ph.D. in Support of Petition for <i>Inter Partes</i> Review of U.S. Patent No. 9,669,069 B2, dated Apr. 26, 2021 (“Gerritsen”) |
| 1004 | Jocelyn Holash et al., <i>VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects</i> , 99 PROC. NAT’L ACAD. SCI. 11393 (2002) (“Holash”) |
| 1005 | Quan Dong Nguyen et al., <i>A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration</i> , 116 OPHTHALMOLOGY 2141 (2009) (“Nguyen-2009”) |
| 1006 | James A Dixon et al., <i>VEGF Trap-Eye for the Treatment of Neovascular Age-Related Macular Degeneration</i> , 18 EXPERT OPINION ON INVESTIGATIONAL DRUGS 1573 (2009) (“Dixon”) |
| 1007 | Adis R&D Profile, <i>Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye</i> , 9 DRUGS R&D 261 (2008) (“Adis”) |
| 1008 | U.S. Patent No. 7,531,173 B2 (“’173 patent”) |

| | |
|------|---|
| 1009 | U.S. Patent No. 7,396,664 B2 (“‘664 patent”) |
| 1010 | U.S. Patent No. 7,374,758 B2 (“‘758 patent”) |
| 1011 | F Semeraro et al., <i>Aflibercept in Wet AMD: Specific Role and Optimal Use</i> , 7 DRUG DESIGN, DEV. & THERAPY 711 (2013) (“Semeraro”) |
| 1012 | Press Release, Regeneron, Regeneron and Bayer Health Care Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration (Apr. 28, 2008), http://investor.regeneron.com/releasedetail.cfm?releaseid=394066 (“Regeneron (28-April-2008)”) |
| 1013 | Press Release, Regeneron, Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration (May 8, 2008), http://investor.regeneron.com/releasedetail.cfm?ReleaseID=394065 (“Regeneron (8-May-2008)”) |
| 1014 | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW1), NCT00509795, ClinicalTrials.gov (Apr. 28, 2009), https://clinicaltrials.gov/ct2/show/NCT00509795 (“NCT-795”) |
| 1015 | VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2), NCT00637377, ClinicalTrials.gov (Mar. 17, 2008), https://clinicaltrials.gov/ct2/show/NCT00637377 (“NCT-377”) |
| 1016 | U.S. Patent Nos. 7,303,746 B2; 7,303,747 B2; 7,306,799 B2; and 7,521,049 B2 (“Monthly-Dosing-Patents”) |
| 1017 | File History of U.S. Patent No. 9,669,069 B2 (“‘069 FH”) |
| 1018 | Jeffrey S. Heier et al., <i>Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration</i> , 119 OPHTHALMOLOGY |

| | |
|------|---|
| | 2537 (2012) (“Heier-2012”) |
| 1019 | U.S. Patent No. 9,254,338 B2 (“338 patent”) |
| 1020 | Jeffrey S. Heier, <i>Intravitreal VEGF Trap for AMD: An Update</i> , RETINA TODAY, Oct. 2009, 44 (“Heier-2009”) |
| 1021 | Regeneron Pharm., Inc., Quarterly Report (Form 10-Q) (Sept. 30, 2009) (“2009 10-Q”) |
| 1022 | U.S. Patent No. 7,374,757 B2 (“757 patent”) |
| 1023 | U.S. Patent No. 7,070,959 B1 (“959 patent”) |
| 1024 | File History of U.S. Patent No. 7,374,758 B2, 12/22/2011 Patent Term Extension Application (“758 FH, 12/22/2011 PTE”) |
| 1025 | Michael Engelbert et al., <i>Long-Term Follow-Up For Type 1 (Subretinal Pigment Epithelium) Neovascularization Using A Modified “Treat And Extend” Dosing Regimen of Intravitreal Antivascular Endothelial Growth Factor Therapy</i> , 30 RETINA, J. RETINAL & VITREOUS DISEASES 1368 (2010) (“Engelbert-2010”) |
| 1026 | Michael Engelbert et al., <i>“Treat and Extend” Dosing of Intravitreal Antivascular Endothelial Growth Factor Therapy For Type 3 Neovascularization/Retinal Angiomatous Proliferation</i> , 29 J. RETINAL & VITREOUS DISEASES 1424 (2009) (“Engelbert-2009”) |
| 1027 | Richard F. Spaide et al., <i>Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity</i> Secondary |

| | |
|------|---|
| | <i>to Central Retinal Vein Occlusion</i> , 147 AM. J.OPHTHALMOLOGY 298 (2009) (“Spaide”) |
| 1028 | Press Release, Regeneron, Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion (Apr. 30, 2009), https://investor.regeneron.com/news-releases/news-release-details/bayer-and-regeneron-extend-development-program-vegf-trap-eye (“Regeneron (30-April-2009)”) |
| 1029 | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO), NCT01012973, ClinicalTrials.gov (Nov. 12, 2009), https://clinicaltrials.gov/ct2/show/NCT01012973 (“NCT-973”) |
| 1030 | P Mitchell et al., <i>Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration: Evidence from Clinical Trials</i> , 94 BRIT. J. OPHTHALMOLOGY 2 (2009) (date of online publication) (“Mitchell”) |
| 1031 | Pascale G. Massin, <i>Anti-VEGF Therapy for Diabetic Macular Edema: An Update</i> , RETINA TODAY, SEPT./Oct. 2008, 54 (“Massin”) |
| 1032 | Press Release, Bayer AG, Bayer and Regeneron Start Additional Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration (May 8, 2008) (“Bayer (8-May-2008)”) |
| 1033 | U.S. Patent Application Publication No. 2006/0217311 A1 (“Dix”) |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.